Hyperliquid Strategies Files S-1 for Resale of 35.16M Shares
Hyperliquid Strategies Inc. filed an S-1 amendment for the resale of up to 35,156,660 shares of common stock by Rorschach Advisors LLC. These shares include 7,761,860 issued shares and 27,394,800 shares issuable upon the exercise of Advisor Warrants, which have varying exercise prices. The company will not receive proceeds from the share sales, and cash proceeds from warrant exercises are unlikely due to a cashless exercise provision. This offering represents approximately 17.9% of the company's outstanding common stock, potentially impacting its trading price. The filing also details the December 2025 business combination with Sonnet BioTherapeutics and Rorschach I LLC, and the subsequent divestment of Sonnet's assets.
Key Highlights
- Resale registration for up to 35,156,660 shares of common stock.
- Selling Securityholder is Rorschach Advisors LLC.
- Includes 7,761,860 Advisor Issued Shares and 27,394,800 Advisor Warrant Shares.
- Advisor Warrants are exercisable at $9.375, $12.50, and $18.75.
- Company will not receive proceeds from the sale of Advisor Shares.
- Advisor Shares represent approximately 17.9% of outstanding common stock.
- Business Combination with Sonnet BioTherapeutics and Rorschach I LLC completed on December 2, 2025.
- Sonnet's assets were subsequently divested to Guidant Biotherapeutics, Inc.
Price Impact
More from PURR